BCRX
BioCryst Pharmaceuticals, Inc.
7.35
+
0.19
2.65%
29 x 7.27
13 x 7.37
bid
ask
21 @ 04:00 PM
7.31-0.04 (0.54%)
Bearish
31
Bullish
79
sentiment
7.07
day range
7.37
6.71
52 week range
14.20
Prev Close7.16
Open7.21
Low7.07
High7.37
Volume1.95M
Avg. Volume2.52M
Market Cap1.39B
Inst. Own87.08%
Beta2.01
Short Ratio12.29
Div & Yield0.00 /
EPS-1.30
P/E0.00
1yr Target15.15
50day MA8.26
200day MA11.26
^DJI
Dow Jones Industrial Average
33963.80
05:35 PM
-
106.60
0.31%
^IXIC
NASDAQ Composite
13211.80
05:15 PM
-
12.20
0.09%
^GSPC
S&P 500
4320.06
05:35 PM
-
9.94
0.23%
AAPL
174.95
+0.16 (0.09%)
Apple Inc.
174.79
9 @ 04:00 PM
9 x 174.93
9 x 175.10
+
0.86
0.49%
GOOG
131.44
+0.19 (0.15%)
Alphabet Inc.
131.25
9 @ 04:00 PM
8 x 131.50
9 x 131.63
-
0.11
0.08%
AMZN
129.30
+0.18 (0.14%)
Amazon.com, Inc.
129.12
9 @ 04:00 PM
8 x 129.27
10 x 129.28
-
0.21
0.16%
MSFT
316.81
-0.20 (0.06%)
Microsoft Corporation
317.01
11 @ 04:00 PM
8 x 316.81
13 x 317.01
-
2.52
0.79%
BABA
88.50
+0.20 (0.23%)
Alibaba Group Holding Limited
88.30
8 @ 04:01 PM
8 x 88.50
8 x 88.58
+
4.19
4.98%
NFLX
379.65
-0.16 (0.04%)
Netflix, Inc.
379.81
10 @ 04:00 PM
9 x 379.82
11 x 380.43
-
4.34
1.13%
TSLA
244.16
-0.72 (0.29%)
Tesla, Inc.
244.88
11 @ 04:00 PM
9 x 243.86
13 x 244.16
-
10.82
4.23%
NVDA
415.74
-0.36 (0.09%)
NVIDIA Corporation
416.10
21 @ 04:00 PM
11 x 415.58
31 x 415.90
+
5.93
1.45%
AMD
96.08
-0.12 (0.12%)
Advanced Micro Devices, Inc.
96.20
13 @ 04:00 PM
14 x 96.01
12 x 96.13
+
0.09
0.09%
MU
68.89
+0.01 (0.01%)
Micron Technology, Inc.
68.88
14 @ 04:00 PM
14 x 68.85
13 x 68.95
+
0.98
1.44%
SPY
430.69
+0.27 (0.06%)
SPDR S&P 500 ETF Trust
430.42
31 @ 04:00 PM
31 x 430.52
30 x 430.80
-
0.97
0.22%
TQQQ
35.68
+0.05 (0.15%)
ProShares UltraPro QQQ
35.63
35 @ 04:00 PM
40 x 35.68
29 x 35.73
+
0.02
0.07%
BRK-A
544000.00
-2215.00 (0.41%)
Berkshire Hathaway Inc.
546215.00
10 @ 04:00 PM
9 x 544500.00
10 x 547042.00
-
4815.00
0.87%
| Day Gain | ||
| Gain | ||
| Market Val | ||
| Costs | ||
| Cash | ||
| Portfolio | ||
| Realized | ||
| Dividend |
News
...
| BioCryst (BCRX) Surges 9.9%: Is This an Indication of Further Gains? | zacks.com • |
| BioCryst Pharmaceuticals rallies on Quebec reimbursement for Orladeyo angioedema treatment | proactiveinvestors.com • |
| BioCryst to Present at Upcoming Investor Conferences | globenewswire.com • |
| BioCryst Pharmaceuticals, Inc. (BCRX) Q2 2023 Earnings Call Transcript | seekingalpha.com • |
| BioCryst Pharmaceuticals (BCRX) Reports Q2 Loss, Tops Revenue Estimates | zacks.com • |
| BioCryst to Report Second Quarter 2023 Financial Results on August 3 | globenewswire.com • |
Profile
...
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor for complement-mediated diseases; and Galidesivir, to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Earning
...
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2023-11-07 | 2023-09 | -0.25 | N/A | N/A | N/A |
| 2023-08-03 | 2023-06 | -0.25 | -0.24 | 0.01 | 4.00% |
| 2023-05-03 | 2023-03 | -0.3 | -0.28 | 0.02 | 6.67% |
| 2023-02-21 | 2022-12 | -0.19 | -0.38 | -0.19 | -100.00% |
| 2022-11-01 | 2022-09 | -0.32 | -0.23 | 0.09 | 28.13% |
| 2022-08-04 | 2022-06 | -0.36 | -0.32 | 0.04 | 11.11% |
Upgrade / Downgrade
...
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2023-07-13 | B of A Securities | Upgrade | Neutral | Buy |
| 2023-05-04 | RBC Capital | Upgrade | Sector Perform | |
| 2023-05-04 | Needham | Upgrade | Buy | |
| 2023-04-20 | Evercore ISI Group | Upgrade | Outperform | |
| 2023-04-20 | Needham | Upgrade | Buy | |
| 2023-03-14 | RBC Capital | Upgrade | Sector Perform |
Insider Holder
...
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2023-06-12 | ABERCROMBIE GEORGE B | Director | 29.61K | Stock Award(Grant) |
| 2023-06-12 | ASELAGE STEPHEN J | Director | 63.34K | Stock Award(Grant) |
| 2023-06-12 | GALSON STEVEN K | Director | 29.61K | Stock Award(Grant) |
| 2023-06-12 | HEGGIE THERESA | Director | 49.11K | Stock Award(Grant) |
| 2023-06-13 | HUTSON NANCY J | Director | 81.82K | Sale |
| 2023-06-12 | LEE KENNETH B. | Director | 68.86K | Stock Award(Grant) |
Institution Ownership
...
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2023-03-30 | Blackrock Inc. | 14.82M | 108.96M | 7.85% |
| 2023-03-30 | Vanguard Group, Inc. (The) | 14.83M | 108.97M | 7.85% |
| 2023-03-30 | Baker Brothers Advisors, LLC | 12.71M | 93.42M | 6.73% |
| 2023-03-30 | State Street Corporation | 11.39M | 83.71M | 6.03% |
| 2023-03-30 | Avoro Capital Advisors LLC | 10.42M | 76.59M | 5.52% |
| 2023-03-30 | Pictet Asset Management SA | 5.62M | 41.30M | 2.97% |
Fund Ownership
...
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2023-02-27 | SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 6.52M | 47.92M | 3.46% |
| 2022-12-30 | Vanguard Total Stock Market Index Fund | 5.65M | 41.54M | 3.00% |
| 2023-02-27 | iShares Russell 2000 ETF | 4.10M | 30.13M | 2.18% |
| 2023-02-27 | Fidelity Select Portfolios - Biotechnology | 2.69M | 19.79M | 1.43% |
| 2022-12-30 | Vanguard Extended Market Index Fund | 2.52M | 18.51M | 1.34% |
| 2022-12-30 | Vanguard Small-Cap Index Fund | 2.40M | 17.65M | 1.27% |
Dividend
...
| Dividend | Date |
|---|---|
| 0 | 2014-06-11 |
| 0 | 2014-06-05 |
| 0 | 2014-05-20 |
| 0 | 2014-05-16 |
| 0 | 2014-04-02 |
This topic has been deleted. Only users with topic management privileges can see it.
-
-
$BCRX I guess we can forget the PLUS huh Jon ?
-
-
$BCRX MartinPlante is delusional he’s a mixed up sea turtle SCAM
-
$BCRX 15 SHARES Pre mkt.
-
$BCRX Marango give it up buddy spew your loser garbage somewhere else move on!
-
$BCRX Glad I’ve got a $1.92 avg.
-
$BCRX this could be the next CCXI….then mabe NOT!
-
$BCRX News flash we are up $3.03 from 3/15/2018 wow!
-
$BCRX I mean sell some more.
-
$BCRX 9 scripts …1.25 scripts per continent Boy we are tearing um up better buy some more shares
-
$BCRX Maphere folded his tent and moved to CLSD a few weeks back
-
$BCRX It’s ashamed this board is turning into a nursery play room
-
$BCRX Another day of baby Joey
-
$BCRX @Joey Go away you lost. Take it like a man move on get off the lot see u later!
-
$BCRX Man oh man holding since 2019 through ups and downs kept the faith but it’s getting hard we are sitting here on a day we should be running and the shorts are sticking it to us what to do
-
$BCRX Let’s get um Horned Frogs
-
-
$BCRX Well we’ve got us a new cry baby
-
BioCryst Pharmaceuticals rallies on Quebec reimbursement for Orladeyo angioedema treatment
proactiveinvestors.com • -
BioCryst to Present at Upcoming Investor Conferences
globenewswire.com • -
BioCryst Pharmaceuticals, Inc. (BCRX) Q2 2023 Earnings Call Transcript
seekingalpha.com • -
BioCryst to Report Second Quarter 2023 Financial Results on August 3
globenewswire.com • -
BioCryst to Present at Upcoming Investor Conference
globenewswire.com • -
BioCryst to Report First Quarter 2023 Financial Results on May 3
globenewswire.com • -
BioCryst to Present at Upcoming Investor Conferences
globenewswire.com • -
BioCryst: Good Candidate For Buyout, But Not For Anything Else
seekingalpha.com • -
BioCryst Is Not Currently Uncovering The Full Value Of ORLADEYO
seekingalpha.com • -
BioCryst to Present at Upcoming Investor Conferences
globenewswire.com • -
BioCryst Pharmaceuticals, Inc. (BCRX) Q4 2022 Earnings Call Transcript
seekingalpha.com • -
BioCryst to Report Fourth Quarter 2022 Financial Results on February 21
globenewswire.com • -
Pharmaceutical Stock Sinks on Sales Forecast
schaeffersresearch.com • -
BioCryst to Present at 41st Annual J.P. Morgan Healthcare Conference
globenewswire.com • -
BioCryst Pharmaceuticals: More Aggressive Growth For Orladeyo
seekingalpha.com • -
BCRX Stock Sinks as BioCryst Discontinues Drug Development
investorplace.com • -
BioCryst to discontinue development of drug
marketwatch.com • -
BioCryst to Present at JMP Securities Hematology & Oncology Summit
globenewswire.com • -
3 Biotechnology stocks under 10 dollars to buy now
thedogofwallstreet.com • -
BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2022 Earnings Call Transcript
seekingalpha.com • -
BioCryst to Report Third Quarter 2022 Financial Results on November 1
globenewswire.com • -
3 Biotech Stocks to Buy Now for Extraordinary Gains
investorplace.com • -
Options Bulls Blast Phama Stock on Lifted Clinical Hold
schaeffersresearch.com • -
3 Fast-Growing Stocks to Buy Now
fool.com • -
BioCryst to Report Second Quarter 2022 Financial Results on August 4
globenewswire.com • -
BioCryst to Present at Upcoming Investor Conference
globenewswire.com • -
BioCryst: A Prudent Diversification
seekingalpha.com • -
7 Cheap Biotech Stocks to Buy Now
investorplace.com • -
BioCryst to Present at Upcoming Investor Conferences
globenewswire.com • -
BioCryst to Report First Quarter 2022 Financial Results on May 5
globenewswire.com • -
Why BioCryst Pharmaceuticals Stock Is Falling
benzinga.com • -
BioCryst to Present at Upcoming Investor Conference
globenewswire.com • -
Why BioCryst Pharmaceuticals Stock Is Plunging Today
benzinga.com • -
BioCryst Provides Tremendous Option Value
seekingalpha.com • -
BioCryst: Great Execution, Impressive Pipeline, Long Cash Runway
seekingalpha.com • -
7 Top Growth Stocks to Buy as We Step Into November
investorplace.com • -
BioCryst to Report Third Quarter 2021 Financial Results on November 3
globenewswire.com • -
7 Best Growth Stocks to Buy and Hold for the Next 10 Years
investorplace.com • -
2 Super-Charged Growth Stocks to Buy Now
fool.com • -
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com • -
NICE Recommends BioCryst's Hereditary Angioedema Med
benzinga.com • -
What Wall Street Still Has Wrong. BioCryst To Become Next Rare Disease Giant
seekingalpha.com • -
BioCryst to Present at Upcoming Investor Conferences
globenewswire.com • -
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com • -
BioCryst Appoints Dr. Steven Galson to Board of Directors
globenewswire.com • -
BioCryst Stock Jumps After Pulling Out $200M Equity Raise
benzinga.com • -
BioCryst Withdraws Public Offering
globenewswire.com • -
BioCryst Pharma Stock Heads Higher Thursday: Here's Why
benzinga.com • -
3 Biotech Stocks That Could Rocket Higher
fool.com • -
BioCryst to Report Second Quarter 2021 Financial Results on August 5
globenewswire.com • -
BioCryst Pharmaceuticals - Orladeyo Revenue Will Drive Share Price
seekingalpha.com •
